This report analyzes the worldwide markets for Antidepressants in Millions of US$. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Latin America. Annual forecasts are provided for each region for the period of 2000 through 2010. The report profiles 45 companies including many key and niche players worldwide such as AstraZeneca PLC, Bristol-Myers Squibb, Eli Lilly and Co., Forest Laboratories, GlaxoSmithKline PLC, H. Lundbeck A/S, Merck & Co., Novartis AG, Organon International, Inc., Pfizer, Inc., Solvay SA, and Wyeth Pharmaceuticals. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.

ANTIDEPRESSANTS									MCP-1383
A GLOBAL STRATEGIC BUSINESS REPORT


                                           CONTENTS


  I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS


 II. EXECUTIVE SUMMARY

  1. Industry Overview                                                  II-1
      Market Highlights                                                 II-1
      Current and Future Analysis                                       II-1
      Industry Dynamics and Changing Scenario                           II-2
      Intense Competition in the Antidepressants Marketplace            II-2
       Global Antidepressants Market (2004): Major Products  in the
        Pipeline                                                        II-3
        Table 1: Leading Brands in the Global Antidepressants Market
        (2001 & 2002): Sales in US$ Million for Seroxat/Paxil,
        Zoloft, Effexor, Cipramil/ Celexa,  Wellbutrin, Prozac,
        Remeron, Fluoxetine Par,  Serzone, and Fluoxetine Barr
        (include  corresponding Graphs/Chart)                           II-4

        Table 2: Leading Drugs in the Global Antidepressants Market
        (2003): Sales in US$ Million for Seroxat,  Zoloft, Effexor,
        Cipramil/ Celexa, Wellbutrin,  Cipralex/ Lexapro, Prozac,
        and Remeron  (include corresponding Graphs/Chart)               II-5
        SSRI/SNRI Brands in the Global Antidepressants Market  (
         2002-2006): Sales in US$ Million by Geographic  Region for
          Cipralex/Lexapro, Effexor, Cipramil/ Celexa, Paxil,
           Zoloft, and Cymbalta                                         II-6
      SSRIs Garnering Major Share of the Market                         II-7
       Table 3: Leading Brands in the Global SSRI Antidepressants
       Market (2003): Percentage Breakdown of Value Sales for
       Zoloft, Paxil and Paxil CR, Generic Fluoxetine, Celexa,
       Lexapro, Prozac, Prozac Weekly, and Others (include
       corresponding Graphs/Chart)                                      II-7
      Emerging Antidepressant Classes Pose Threat to SSRI               II-8
      Market Snapshots                                                  II-8

  2. Market Trends & Issues                                             II-9
      New Drugs Making Way into the Market                              II-9
      Prozac Patent Expiry Opens Door for Generic Versions              II-9
      Generic Antidepressants to Hit Market Soon                        II-9
      TCA Antidepressants Still in Use                                  II-10
      Improved Marketing Spurs Growth                                   II-10
      Westerners Fight Depression Blues; Americans  Top the List        II-10
      Antidepressants High in Demand but Fail to Satisfy  Consumers     II-10
      No One is Immune: Not Even Animals!                               II-11
      Patent Expiry Disturbs Antidepressants Producers                  II-11
      Unlicensed Antidepressants Pose Danger to  Youth Safety           II-11
       Global Antidepressants Market (2003): Regulations  Governing
        Select Antidepressants Use in Children                          II-12
      Growing Safety Concerns - Antidepressants Under Fire              II-12
       The Debate Flares                                                II-12
       Are Antidepressants Totally Safe? A Moot but  Important Question II-12
       Manufacturers Vociferous in their Protests                       II-13
       No Satisfactory Answers Yet - The Wait Grows Longer              II-13
        Global Antidepressants Market: Drug Regulation for  Kids in
         Britain and the United States                                  II-13

  3. Depression: A Mental Review                                        II-14
      What is depression?                                               II-14
      Symptoms of Depression                                            II-14
      Causes of Depression                                              II-14
      Types of Depression and Related Disorders                         II-15
       Major Depressive Disorders (Major Depression)                    II-15
       Dysthymic Disorder (Minor Depression)                            II-15
       Bipolar Disorder                                                 II-15
      Related Disorder Types                                            II-15
       Seasonal Affective Disorder                                      II-16
       Premenstrual Dysphoric Disorder (PMDD)                           II-16
       Anxiety Disorders                                                II-16
       Obsessive Compulsive Disorder                                    II-16
       Generalized Anxiety Disorder                                     II-16
       Panic Disorder                                                   II-16
      Treatment of Depression                                           II-16
       Options Available in Depression Treatment                        II-17
        Psychotherapy or Psychiatric Consultation                       II-17
        Pharmacotherapy                                                 II-17
        Combination of Psychotherapy and Pharmacotherapy                II-17
        Herbal and Nutritional Treatment                                II-17
        Exercise                                                        II-17
       How Can Depression Treatment become More  Effective?             II-17
        Global Antidepressants Market: Favorable Drugs  Under
         Specific Conditions                                            II-18
        Global Antidepressants Market: Unfavorable  Drugs Under
         Specific Conditions                                            II-18
      Treatment-Resistant Depression (TRD)                              II-19
       Optimizing the Dosage                                            II-19
       Switching of Medications                                         II-19
       Combination therapy                                              II-19
       Augmentation Therapy                                             II-19
       Electroconvulsive Therapy                                        II-19
      Facts and Figures on Depression                                   II-20
       Table 4: Global Antidepressants Market (2004): Percentage
       Breakdown of Prevalence Rate by Disorder Type - Depression,
       Anxiety, Obsessive Compulsive Disorder,  Sleep Disorder,
       Panic Disorder, Phobias, and Others  (include corresponding
       Graphs/Chart)                                                    II-20
      Depression Hits the Elderly Hard                                  II-20
      Men Vs Women - Who is More Depression Prone?                      II-21
      Depression and Smoking - Interlinked to One Another               II-22

  4. Product Analysis                                                   II-23
      What are Antidepressants? A Clear Understanding                   II-23
      Global Antidepressants Market (2004): Select Brands  and their
       Manufacturers                                                    II-23
      Application Areas                                                 II-23
       Select Antidepressants and their Applications                    II-24
      Types of Antidepressants                                          II-24
       Tricyclic Antidepressants (TCAs)                                 II-25
        Global Antidepressants Market: TCA Brands and Dosage  Types
         - Starting Dosage and Normal Dosage                            II-25
        Global Antidepressants Market: TCAs and their  Side Effects     II-26
       Monamine Oxidase Inhibitors (MAOIs)                              II-26
        Global Antidepressants Market: MAOI Brands and Dosage  Types
         - Starting Dosage and Normal Dosage                            II-26
        Side Effects of Different MAOIs - Tranylcypromine;
         Isocarboxazid and Phenelzine                                   II-27
       Selective Serotonin Reuptake Inhibitors (SSRIs)                  II-27
        Global Antidepressants Market: SSRIs Brands and Related
         Dosage - Starting Dosage and Normal Dosage                     II-27
        Pharmacology                                                    II-27
        FDA Approval                                                    II-28
         Fluoxetine (Proxac)                                            II-28
         Citalopram                                                     II-28
         Fluvoxamine (Luvox)                                            II-28
         Paroxetine                                                     II-29
         Sertraline (Zoloft)                                            II-29
         Escitalopram                                                   II-29
        Side Effects                                                    II-29
         Global Antidepressants Market: Different SSRI  Drugs and
          their Side Effects                                            II-30
        Applications                                                    II-30
         Global Antidepressants Market: SSRIs' Off-Label
          Application Areas and Medication                              II-30
       New Generation Antidepressants                                   II-31
        Dopamine-Reuptake Blocking Compounds                            II-31
         Bupropion                                                      II-31
        Serotonin and Noradrenaline Reuptake Inhibitors                 II-31
         Venlafaxine                                                    II-31
        5HT2 Receptor Antagonist Properties                             II-32
         Nefazodone                                                     II-32
         Trazodone                                                      II-32
        Noradrenergic Antagonist                                        II-32
         Mirtazapine                                                    II-32
         Global Antidepressants Market: New Generation  Drugs and
          Dosage Types - Starting Dosage  and Normal Dosage             II-33
          Global Antidepressants Market: New Generation
           Antidepressants and their Side Effects                       II-33
         Global Antidepressants Market: Major Drugs by  Class -
          SSRI, SNRI, MAOI, and NaSSA                                   II-34

  5. Antidepressants: An In-Depth Analysis                              II-35
      Tracing the Line of History                                       II-35
       Antidepressants, a Mere Accidental Discovery                     II-35
       Limited Choices and High Risk Rates                              II-35
       Better Alternatives and Wider Choice - The New Mantra            II-35
        Global Antidepressants Market: Launch of Drug Types -  TCAs,
         MAOI, SSRI, and New Generation Variants  by Original
          Version, Secondary Version,  and Generic Version              II-36
       Adverse Effects of Antidepressants and their  Management         II-37
        Sedation                                                        II-37
        Orthostatic Hypotension                                         II-37
        Insomnia                                                        II-37
        Anticholinergic Effects                                         II-38
        Weight Gain/Loss                                                II-38
        Sexual Dysfunction                                              II-38
        Side Effects Associated with Overdose                           II-38
      Choosing an Antidepressant                                        II-39
       Table 5: Global Antidepressants Market: Percentage Breakdown
       of Volume Drug Consumption by Disorder Type - Depression,
       Generalized Anxiety Disorder, Post Traumatic Stress Disorder,
       Panic Disorder and Others (include corresponding
       Graphs/Chart)                                                    II-39
      Switching Antidepressants                                         II-40
      Do Antidepressants Treat Depression Completely?                   II-40
      Are Antidepressants Addictive?                                    II-41
       Global Antidepressants Market: Withdrawal Symptoms  by Drug
        Types - TCAs and SSRIs                                          II-41
      Disorders and Antidepressants                                     II-42
       Bipolar Disorder                                                 II-42
       Anxiety Disorder                                                 II-42
        Panic Disorder                                                  II-42
         Antidepressants Used for Treatment of Panic  Disorders,
          their Efficacy/Recommendations,  and Side Effects             II-43
         A Note of Caution for Panic Patients Using  Antidepressants    II-43
        Generalized Anxiety Disorder                                    II-43
         SNRI                                                           II-44
         SSRI                                                           II-44
         TCAs                                                           II-44
          Antidepressants Used for Treatment of Anxiety  Disorders      II-44
      Antidepressants: Causes For and Against                           II-45
       Cause for Antidepressants:                                       II-45
        Antidepressants Effective in Curing Premenstrual Dysphoric
         Disorder                                                       II-45
        Antidepressants Offer Solution for Itching and Scratching       II-46
        Antidepressants Offer Hope for Autistic Children                II-46
        Antidepressants Minimize Hot Flushes and  Night Sweats          II-46
        Antidepressants' Positive Effect on the Brain                   II-47
        Longer Duration Antidepressants Treatment  Prevents Relapse     II-47
        Antidepressants - A New Option for Sleep Apnea                  II-47
        SSRI Antidepressants May Prove Helpful in  Cancer Treatment     II-48
        Antidepressants Relaxes Tremors                                 II-48
        Lesser Fear of Breast Cancer with Antidepressants               II-48
        Antidepressants for Reducing Chronic Back Pain                  II-48
       Causes Against Antidepressants                                   II-48
        Greater Heart at Risk with Antidepressants                      II-48
        Antidepressants Dissipates Sexual Drive                         II-49
        Hip Fractures Troubles Aged Patients                            II-49
        Antidepressants can be a Deadly Prescription  for Kids          II-50
        Dental Problems with Antidepressants                            II-50
      Facts/Myths About Antidepressants                                 II-50
       Are Pregnant Women at Risk from Antidepressants?                 II-50
       Is Breast Feeding Safe While on Antidepressants?                 II-51
       Homeopathic Treatment Versus Antidepressants  Treatment -
        Which is Better?                                                II-51
       Recent Findings on Antidepressants                               II-52

  6. Technological Developments                                         II-53
      Monitoring Technology Foresees Antidepressants  Effect            II-53
      Vagus Nerve Stimulation - Device for Treating  Depression         II-53
      Global Antidepressants Market: FDA Approvals  (2002-2004)         II-53

  7. Product Introductions/Innovations                                  II-54
      GlaxoSmithKline Re-Introduces Paxil CR in US Market               II-54
      Ratiopharm Launches Ratio-Paroxetine in Canada                    II-54
      Organon Introduces Zispin SolTab                                  II-54
      Apotex Releases Generic Version of Paxil                          II-54
      GlaxoSmithKline Launches Paxil CR                                 II-54
      Lundbeck Launches Lexapro                                         II-55

  8. Recent Industry Activity                                           II-56
      Pfizer Acquires Esperion                                          II-56
      Organon in Marketing Agreement with STADA                         II-56
      Andrx Signs Marketing Agreement with Impax and Teva               II-56
      GlaxoSmithKline Collaborates with NeuroSearch                     II-56
      Lundbeck in Marketing Accord with Janssen-Cilag                   II-56
      Lundbeck Allies with Abbott Laboratories                          II-57
      Myriad Signs an Agreement with Abbott Laboratories                II-57
      Recordati Obtains Marketing Rights from H Lundbeck                II-57

  9. Focus on Select Global Players                                     II-58
      AstraZeneca Plc (UK)                                              II-58
      Bristol-Myers Squibb (USA)                                        II-58
      Eli Lilly and Co. (USA)                                           II-58
      Forest Laboratories (USA)                                         II-59
      GlaxoSmithKline Plc (UK)                                          II-59
      H. Lundbeck A/S (Denmark)                                         II-60
      Merck & Co. (USA)                                                 II-60
      Novartis AG (Switzerland)                                         II-60
      Organon International, Inc. (USA)                                 II-60
      Pfizer, Inc. (USA)                                                II-61
      Solvay SA (Brussels)                                              II-61
      Wyeth Pharmaceuticals (USA)                                       II-61

  10. Global Market Perspective                                         II-63
      Table 6: World Recent Past, Current & Future Analysis for
      Antidepressants by Geographic Region - USA, Canada, Japan,
      Europe, Asia-Pacific (excluding Japan), and Latin America
      Markets Independently Analyzed with Annual Sales  Figures in
      US$ Million for Years 2000 through 2010  (include
      corresponding Graphs/Chart)                                       II-63

      Table 7: World 10-Year Perspective for Antidepressants  by
      Geographic Region - Percentage Breakdown of  Dollar Sales for
      USA, Canada, Japan, Europe,  Asia-Pacific (excluding Japan),
      and Latin America  Markets for Years 2000, 2005 & 2010
      (include  corresponding Graphs/Chart)                             II-64


III. MARKET

  1. The United States                                                  III-1
      A.Market Analysis                                                 III-1
        Current and Future Analysis                                     III-1
        Market Overview                                                 III-1
         Antidepressants Usage in the United States                     III-1
         US Antidepressants Market: Drug Usage                          III-2
        Competitive Scenario                                            III-2
         Table 8:Leading Players in the US Antidepressants Market
         (2004 & 2005(E)): Percentage Breakdown  of Value Sales for
         Forest Labs, GlaxoSmithKline,  Pfizer, Wyeth, Eli Lilly and
         Others (include  corresponding Graphs/Chart)                   III-2

         Table 9: Leading Players in the US SSRI/SNRI Market (2004 &
         2005(E)): Percentage Breakdown of  Value Sales for Forest
         Labs, Pfizer, Wyeth,  GlaxoSmithKline, Eli Lilly and Others
         (include corresponding Graphs/Chart)                           III-3
        Trends and Issues                                               III-3
         Are Americans Getting Too Depressed?                           III-3
         New Drugs Set to Conquer the Market                            III-4
          Table 10: Leading SSRI/ SNRI Brands in the US
          Antidepressants Market (2000-2005(E)): Percentage
          Breakdown of Sales for Prozac, Paxil, Zoloft,  Celexa,
          Lexapro, Effexor and Others  (include corresponding
          Graphs/Chart)                                                 III-4

          Table 11: US Antidepressants Market (2000-2003): Number of
          SSRI/SNRI Prescriptions Dispensed in Millions (include
          corresponding Graphs/Chart)                                   III-5

          Table 12: US Antidepressants Market (2000): Advertising
          Expenditure in US$ Million on Select  SSRIs - Celexa
          (Citalopram), Prozac (Fluoxetine), Effexor XR
          (Venlafaxine), Zoloft (Sertraline),  Paxil (Paroxetine),
          and Luvox (Fluvoxamine)  (include corresponding
          Graphs/Chart)                                                 III-5
         Depression More Common Among Gays                              III-5
         FDA Inspects Suicidal Tendencies in Kids on  Antidepressants   III-6
         FDA Imposes "black-box" Warning                                III-6
         Generic Drugs Pose Competition to Branded Drugs                III-7
          Table 13: Leading SSRI Brands in the US Antidepressants
          Market (2001): Sales in US$ Million for Zoloft, Paxil,
          Prozac & Sarafem, Celexa, and  Luvox (include
          corresponding Graphs/Chart)                                   III-7
          Depression Drugs Being Used for Symptoms Other  Than
           Depression                                                   III-7
          US Antidepressants Market: Drugs Approved  for Different
           Indications                                                  III-8
         Frequent Patent Expiries - A Cause of Concern  for
          Manufacturers                                                 III-8
         Patent Expiry of Select Antidepressant Brands  in the
          United States                                                 III-8
        Product Launches/Developments                                   III-9
        Strategic Corporate Developments                                III-10
        Key Players                                                     III-10
         Bristol-Myers Squibb                                           III-10
         Eli Lilly and Co.                                              III-11
         Forest Laboratories                                            III-11
         Merck & Co.                                                    III-11
         Organon International, Inc.                                    III-12
         Pfizer, Inc.                                                   III-12
         Wyeth Pharmaceuticals                                          III-12
      B.Market Analytics                                                III-13
        Table 14: US Recent Past, Current & Future Analysis for
        Antidepressants by Product Segment - SSRI, New Generation,
        TCA and MAOI Independently Analyzed  with Annual Sales
        Figures in US$ Million for  Years 2000 through 2010 (include
        corresponding Graphs/Chart)                                     III-13

        Table 15: US 10-Year Perspective for Antidepressants by
        Product Segment - Percentage Breakdown of Dollar  Sales for
        SSRI, New Generation, TCA and  MAOI for Years 2000, 2005 &
        2010 (include  corresponding Graphs/Chart)                      III-14

  2. Canada                                                             III-15
      A.Market Analysis                                                 III-15
        Current and Future Analysis                                     III-15
        Market Overview                                                 III-15
         Increasing Use of Antidepressants among Canadian  Women        III-15
        Antidepressants Market - A Recent Past Perspective              III-15
         Table 16: Canadian Antidepressants Market (2001):
         Percentage Breakdown of Value Sales by Class -  SSRI, TCAs,
         MOAI, and Others (include  corresponding Graphs/Chart)         III-16
        Generic Serzone Recalled from Canadian  Market in 2003          III-16
        Warning Against Antidepressants Use in Under- 18 Age Group      III-16
        Product Launch                                                  III-17
      B.Market Analytics                                                III-17
        Table 17: Canadian Recent Past, Current & Future  Analysis
        for Antidepressants: Annual Sales Figures  in US$ Million
        for Years 2000 through 2010  (include corresponding
        Graphs/Chart)                                                   III-17

  3. Japan                                                              III-18
      A.Market Analysis                                                 III-18
        Current and Future Analysis                                     III-18
        Recent Past Perspective                                         III-18
         Table 18: CNS Market in Japan (2001): Sales in US$ Million
         by Drug Class - Antidepressants, Antiulcerants, Cholesterol
         Reducers, Broad Antibiotic, Antiarrhythmic,
         Antihypertensive, Narcotic painkiller, Oral  Diabetes, Oral
         Antihistamine, and Antiseizure  (include corresponding
         Graphs/Chart)                                                  III-19
        Competitive Scenario                                            III-19
         Table 19: Leading Brands in the Japanese Antidepressants
         Market (2001 & 2002): Percentage Breakdown of Value Sales
         for Paxil, Luvox,  Depromel, Ludiomil, Toledomin,
         Toledomin- Jansen, Anafranil, Tetramide, and Others
         (include corresponding Graphs/Chart)                           III-20
        A Historical Perspective                                        III-20
        Antidepressants Market in Japan - Major Drug  Launches the
         Period 1973-2000                                               III-21
      B.Market Analytics                                                III-22
        Table 20: Japanese Recent Past, Current & Future  Analysis
        for Antidepressants: Annual Sales Figures  in US$ Million
        for Years 2000 through 2010  (include corresponding
        Graphs/Chart)                                                   III-22

  4. Europe                                                             III-23
      A.Market Analysis                                                 III-23
        Current and Future Analysis                                     III-23
        Market Overview                                                 III-23
         Table 21: Leading Players in the European Antidepressants
         Market (2004 & 2005(E)) - Percentage Breakdown of Value
         Sales for GlaxoSmithKline,  Eli Lilly, Lundbeck, Pfizer,
         Wyeth and Others  (include corresponding Graphs/Chart)         III-24
        Changes in European Patent Litigation                           III-24
        Strategic Corporate Developments                                III-24
      B.Market Analytics                                                III-25
        Table 22: European Recent Past, Current & Future Analysis
        for Antidepressants by Geographic Region - France, Germany,
        UK, Italy, Spain, and Rest of Europe Markets Independently
        Analyzed with Annual Sales Figures in  US$ Million for Years
        2000 through 2010 (include corresponding Graphs/Chart)          III-25

        Table 23: European 10-Year Perspective for Antidepressants
        by Geographic Region - Percentage Breakdown of Dollar Sales
        for France, Germany,  UK, Italy, Spain, and Rest of Europe
        Markets for  Years 2000, 2005 & 2010 (include corresponding
        Graphs/Chart)                                                   III-26

  4a. France                                                            III-27
       Market Analysis                                                  III-27
        Current and Future Analysis                                     III-27
         Table 24: French Recent Past, Current & Future Analysis for
         Antidepressants: Annual Sales Figures in  US$ Million for
         Years 2000 through 2010  (include corresponding
         Graphs/Chart)                                                  III-27

  4b. Germany                                                           III-28
       Market Analysis                                                  III-28
        Current and Future Analysis                                     III-28
         Table 25: German Recent Past, Current & Future Analysis for
         Antidepressants: Annual Sales Figures  in US$ Million for
         Years 2000 through 2010  (include corresponding
         Graphs/Chart)                                                  III-28

  4c. The United Kingdom                                                III-29
      A.Market Analysis                                                 III-29
        Current and Future Analysis                                     III-29
        Market Overview                                                 III-29
        A Recent Past Perspective                                       III-29
         UK Bans Antidepressant Use in Children (2003)                  III-29
          Table 26: Antidepressants Market in the UK (1993-2000):
          Number of Associated Deaths in England and Wales by Drug
          Class - TCAs, MAOIs, SSRIs and  Others (include
          corresponding Graphs/Chart)                                   III-30
         Prescriptions and Expenditure Statistics                       III-30
        Regional Analysis - Scotland                                    III-30
         Antidepressants, a Happy Pill for Sad Scots                    III-30
        Key Players                                                     III-31
         AstraZeneca                                                    III-31
         GlaxoSmithKline                                                III-31
      B.Market Analytics                                                III-32
        Table 27: UK Recent Past, Current & Future Analysis  for
        Antidepressants: Annual Sales Figures in  US$ Million for
        Years 2000 through 2010  (include corresponding
        Graphs/Chart)                                                   III-32

  4d. Italy                                                             III-33
       Market Analysis                                                  III-33
        Current and Future Analysis                                     III-33
         Table 28: Italian Recent Past, Current & Future  Analysis
         for Antidepressants: Annual Sales Figures  in US$ Million
         for Years 2000 through 2010  (include corresponding
         Graphs/Chart)                                                  III-33

  4e. Spain                                                             III-34
       Market Analysis                                                  III-34
        Current and Future Analysis                                     III-34
         Table 29: Spanish Recent Past, Current & Future  Analysis
         for Antidepressants: Annual Sales Figures  in US$ Million
         for Years 2000 through 2010  (include corresponding
         Graphs/Chart)                                                  III-34

  4f. Rest of Europe                                                    III-35
      A.Market Analysis                                                 III-35
        Current and Future Analysis                                     III-35
        Focus on Select Regional Markets                                III-35
        Denmark                                                         III-35
         Danish People Display Greater Preference for  Antidepressants  III-35
        Finland                                                         III-35
         Antidepressants Consumption Increases Among  Young Adults      III-35
        Key Players                                                     III-35
         H. Lundbeck A/S (Denmark)                                      III-35
         Novartis AG (Switzerland)                                      III-36
         Solvay SA (Brussels)                                           III-36
      B.Market Analytics                                                III-36
        Table 30: Rest of Europe Recent Past, Current &  Future
        Analysis for Antidepressants: Annual  Sales Figures in US$
        Million for Years  2000 through 2010 III-34 (include
        corresponding Graphs/Chart)                                     III-36

  5. Asia-Pacific                                                       III-37
      A.Market Analysis                                                 III-37
        Current and Future Analysis                                     III-37
        Australia                                                       III-37
         A Recent Past Market Perspective                               III-37
         Commonly Used Antidepressants in Australia  (2001)             III-37
        Strategic Corporate Development                                 III-38
      B.Market Analytics                                                III-38
        Table 31: Asia-Pacific Recent Past, Current &  Future
        Analysis for Antidepressants: Annual  Sales Figures in US$
        Million for Years  2000 through 2010 (include corresponding
        Graphs/Chart)                                                   III-38

  6. Latin America                                                      III-39
      A.Market Analysis                                                 III-39
        Current and Future Analysis                                     III-39
        Chile                                                           III-39
         High Usage of Antidepressants among Chileans                   III-39
        Strategic Corporate Development                                 III-39
      B.Market Analytics                                                III-40
        Table 32: Latin America Recent Past, Current &  Future
        Analysis for Antidepressants: Annual  Sales Figures in US$
        Million for Years  2000 through 2010 (include corresponding
        Graphs/Chart)                                                   III-40


 IV. COMPETITIVE LANDSCAPE